Identifiable gaps in health outcomes piqued my research interests. I now work with patients, families, clinicians and researchers to improve care and outcomes for children and families using learning health networks. These networks, used for improvement and research, can accelerate population health outcomes at scale.
Working with my colleagues, we determined that the Learning Health Network model reliably reproduces results at scale. This model has already been effective for networks focusing on chronic conditions, rare diseases, safety and population health.
I joined Cincinnati Children’s Hospital Medical Center in 2006 to research learning health networks, collaborative science, quality improvement, and patient and family partnerships. All the outcomes I’ve achieved have come as a direct result of partnering with others.
Patient and family care has been truly transformative for me. The experience has helped me dramatically improve our learning health network outcomes. Additionally, improvement science has helped me understand the value of standardization, since the reliability of processes and results supports a platform for innovation.
As a result of my work, I have been honored with the 2020 Cincinnati Children’s Advocacy Award. I also serve as the senior quality advisor for the American Board of Pediatrics.
MD: University of Minnesota Medical School, Twin Cities, MN, 1982.
Residency: Medicine-Pediatrics, University of North Carolina, Chapel Hill, NC.
Fellowship: Robert Wood Johnson Clinical Scholars Program, University of North Carolina, Chapel Hill, NC.
MPH: University of North Carolina, Epidemiology, Chapel Hill, NC, 1993.
Certification: Internal Medicine, 1986; Pediatrics, 1988.
Quality Improvement
The impact of being Black while living with a chronic condition: Inpatient perspectives. Journal of hospital medicine (Online). 2023.
Naloxone Education and Receipt of Kit During the Perinatal Period. American Journal of Obstetrics and Gynecology. 2023; 228:s208-s209.
Abstract 12509: Characterization and Risk Factors for Death or Transplant After Stage Ii/glenn Palliation in Infants With Single Ventricle Heart Disease. Circulation. 2022; 146:a12509-a12509.
Digoxin Associated With Greater Transplant-Free Survival in High- vs Low-Risk Interstage Patients. Annals of Thoracic Surgery. 2022; 114:1453-1459.
Framework to optimise learning network activities for long-term success. BMJ Quality and Safety. 2022.
Quality Improvement Initiative to Improve Healthcare Providers' Attitudes towards Mothers with Opioid Use Disorder. Pediatric Quality and Safety. 2021; 6.
Characteristics of Interstage Death After Discharge from Stage I Palliation. Pediatric Cardiology. 2021; 42:1372-1378.
A maturity grid assessment tool for learning networks. Learning Health Systems. 2021; 5.
The future is now for transforming outcomes nationally: the Fontan Outcomes Network. Progress in Pediatric Cardiology. 2020; 59.
Development of a validated risk score for interstage death or transplant after stage I palliation for single-ventricle heart disease. Journal of Thoracic and Cardiovascular Surgery. 2020; 160:1021-1030.
Carole Lannon, MD, MPH, Christine L. Schuler, MD, MPH2/21/2023
Carole Lannon, MD, MPH, Thomas F. Boat, MD1/9/2020